Curis (NASDAQ: CRIS) and GTx (NASDAQ:GTXI) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, dividends, earnings, institutional ownership and profitability.

Analyst Ratings

This is a breakdown of recent recommendations for Curis and GTx, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Curis 0 0 4 0 3.00
GTx 0 1 0 0 2.00

Curis presently has a consensus target price of $6.67, indicating a potential upside of 262.32%. GTx has a consensus target price of $1.00, indicating a potential downside of 82.73%. Given Curis’ stronger consensus rating and higher possible upside, equities analysts plainly believe Curis is more favorable than GTx.

Volatility & Risk

Curis has a beta of 1.88, suggesting that its stock price is 88% more volatile than the S&P 500. Comparatively, GTx has a beta of 1.66, suggesting that its stock price is 66% more volatile than the S&P 500.

Institutional & Insider Ownership

51.8% of Curis shares are owned by institutional investors. Comparatively, 9.5% of GTx shares are owned by institutional investors. 4.1% of Curis shares are owned by company insiders. Comparatively, 41.2% of GTx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Curis and GTx’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Curis -836.18% -236.43% -88.44%
GTx N/A -160.78% -128.57%

Valuation and Earnings

This table compares Curis and GTx’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Curis $8.31 million 31.86 -$48.51 million ($0.50) -3.68
GTx N/A N/A -$26.09 million ($1.73) -3.35

GTx has higher revenue, but lower earnings than Curis. Curis is trading at a lower price-to-earnings ratio than GTx, indicating that it is currently the more affordable of the two stocks.

Summary

Curis beats GTx on 8 of the 12 factors compared between the two stocks.

Curis Company Profile

Curis, Inc. is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target programmed death ligand-1 (PDL1) and V-domain Ig suppressor of T-cell activation (VISTA) immune checkpoint proteins, both of which independently function as negative regulators of immune activation. CA-4948 is an oral small molecule drug candidate that is designed to inhibit the Interleukin-1 receptor-associated kinase 4 (IRAK4) kinase, which is a transducer of toll-like receptor or certain interleukin receptor signaling pathways.

GTx Company Profile

GTx, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs). Its lead product candidate, enobosarm (GTx-024), had been evaluated in over 24 completed or ongoing clinical trials, including in approximately six Phase II and two Phase III clinical trials. The Company is also engaged in the development of GTx-758 (Capesaris), an oral nonsteroidal selective estrogen receptor alpha agonist, for secondary hormonal therapy in men with metastatic and high-risk non-metastatic castration resistant prostate cancer (CRPC). Its product candidate, Enobosarm, for the treatment of women with advanced androgen receptor (AR) positive triple-negative breast cancer (TNBC), is in Phase II clinical development-stage.

Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.